M&A Deal Summary

Horizon Therapeutics Acquires Nuvo Research - PENNSAID

On October 17, 2014, Horizon Therapeutics acquired life science company Nuvo Research - PENNSAID from Miravo Healthcare for 45M USD

Acquisition Highlights
  • This is Horizon Therapeutics’ 3rd transaction in the Life Science sector.
  • This is Horizon Therapeutics’ 9th largest (disclosed) transaction.
  • This is Horizon Therapeutics’ 3rd transaction in the United States.

M&A Deal Summary
Date 2014-10-17
Target Nuvo Research - PENNSAID
Sector Life Science
Buyer(s) Horizon Therapeutics
Sellers(s) Miravo Healthcare
Deal Type Divestiture
Deal Value 45M USD

Target

Nuvo Research - PENNSAID

United States
Nuvo Research - PENNSAID 2% is a second generation version of PENNSAID® (diclofenac sodium topical solution) 1.5% w/w (PENNSAID 1.5%).

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Horizon Therapeutics

Dublin, Ireland

website

Category Company
Founded 2005
Sector Life Science
Employees2,100
Revenue 3.2B USD (2021)
DESCRIPTION

Horizon Therapeutics is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon Therapeutics was founded in 2005 and is based in Dublin, Ireland.

DEAL STATS #
Overall 3 of 11
Sector (Life Science) 3 of 11
Type (Divestiture) 2 of 4
Country (United States) 3 of 9
Year (2014) 2 of 2
Size (of disclosed) 9 of 10
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-03-19 Vidara Therapeutics

Alpharetta, Georgia, United States

Vidara is a specialty pharmaceutical company focused on acquiring, licensing, developing and marketing specialty pharmaceutical products targeting Orphan disease states, hospital or critical care settings and other niche therapeutic treatment areas. The company’s mission is to serve the critical pharmaceutical treatment needs of targeted, patient populations where other larger companies choose not to focus.

Buy $660M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-04-03 Hyperion Therapeutics

Brisbane, California, United States

Hyperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company committed to developing and delivering life-changing treatments for orphan diseases.

Buy $1.1B

Seller(S) 1

SELLER

Miravo Healthcare

Mississauga, Ontario, Canada

website

Category Company
Founded 1983
Sector Healthcare Services
Employees100
Revenue 69M CAD (2021)
DESCRIPTION

Miravo Healthcare is a specialty pharmaceutical company with a diverse portfolio of products and technologies. Miravo Healthcare was founded in 1983 and is based in Mississauga, Canada.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (United States) 1 of 1
Year (2014) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-08-10 Aralez Pharmaceuticals - VIMOVO Royalties

Milton, Ontario, Canada

Aralez Pharmaceuticals, Inc. - VIMOVO Royalties is a provider of biotechnological services in Milton, Canada.

Buy $110M
Mergr

Product

Company

Legal